Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

ProPhase Labs (PRPH) Invested Capital (2016 - 2025)

Historic Invested Capital for ProPhase Labs (PRPH) over the last 16 years, with Q3 2025 value amounting to $10.4 million.

  • ProPhase Labs' Invested Capital fell 7724.27% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year decrease of 7724.27%. This contributed to the annual value of $12.1 million for FY2024, which is 7819.76% down from last year.
  • Per ProPhase Labs' latest filing, its Invested Capital stood at $10.4 million for Q3 2025, which was down 7724.27% from $16.0 million recorded in Q2 2025.
  • ProPhase Labs' Invested Capital's 5-year high stood at $68.2 million during Q2 2022, with a 5-year trough of $10.4 million in Q3 2025.
  • Its 5-year average for Invested Capital is $48.4 million, with a median of $52.7 million in 2021.
  • Its Invested Capital has fluctuated over the past 5 years, first surged by 45539.98% in 2021, then tumbled by 7819.76% in 2024.
  • Quarter analysis of 5 years shows ProPhase Labs' Invested Capital stood at $58.6 million in 2021, then increased by 8.53% to $63.6 million in 2022, then decreased by 13.12% to $55.3 million in 2023, then crashed by 78.2% to $12.1 million in 2024, then dropped by 13.66% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $16.0 million for Q2 2025, and $19.7 million during Q1 2025.